BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baba AB, Rah B, Bhat GR, Mushtaq I, Parveen S, Hassan R, Hameed Zargar M, Afroze D. Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within. Front Pharmacol 2022;13:791272. [DOI: 10.3389/fphar.2022.791272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Thatikonda S, Pooladanda V, Tokala R, Nagula S, Godugu C. Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells. Toxicol In Vitro 2023;89:105579. [PMID: 36870549 DOI: 10.1016/j.tiv.2023.105579] [Reference Citation Analysis]
2 Pejčić T, Todorović Z, Đurašević S, Popović L. Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. Int J Mol Sci 2023;24. [PMID: 36769263 DOI: 10.3390/ijms24032939] [Reference Citation Analysis]
3 Abbona A, Ricci V, Paccagnella M, Granetto C, Ruatta F, Cauchi C, Galizia D, Ghidini M, Denaro N, Merlano MC, Garrone O. Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib. Vaccines (Basel) 2023;11. [PMID: 36851213 DOI: 10.3390/vaccines11020335] [Reference Citation Analysis]
4 Li Z, Wang H, Wang Y, Ma Z, Hu L, Luo S, Gong Y, Zhu L, Gong H, Xiang R, Zhu Y, Xie Y, Yang C, Peng H, Liu J, Xiao X. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma. Cancer Lett 2023;554:216019. [PMID: 36442773 DOI: 10.1016/j.canlet.2022.216019] [Reference Citation Analysis]
5 Lin TY, Lo HC, Qiu WL, Chao CH, Lu MK, Hsu HY. Biochemical characterization and anti-cancer activity of tangential flow filtration system assisted purification of fucoglucan from Laminaria japonica. Int J Biol Macromol 2023;227:1-9. [PMID: 36528139 DOI: 10.1016/j.ijbiomac.2022.12.078] [Reference Citation Analysis]
6 Patra D, Bhavya K, Ramprasad P, Kalia M, Pal D. Anti-cancer drug molecules targeting cancer cell cycle and proliferation. Advances in Protein Chemistry and Structural Biology 2023. [DOI: 10.1016/bs.apcsb.2022.11.011] [Reference Citation Analysis]
7 Price ZK, Lokman NA, Yoshihara M, Kajiyama H, Oehler MK, Ricciardelli C. Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. Int J Mol Sci 2022;24. [PMID: 36614139 DOI: 10.3390/ijms24010696] [Reference Citation Analysis]
8 Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, Katuch V. Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer. World J Gastroenterol 2022; 28(33): 4744-4761 [DOI: 10.3748/wjg.v28.i33.4744] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Guler S, Zik B, Yalcin A. Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells. Mol Biol Rep 2022. [PMID: 36053282 DOI: 10.1007/s11033-022-07893-1] [Reference Citation Analysis]
10 Drakulic D, Schwirtlich M, Petrovic I, Mojsin M, Milivojevic M, Kovacevic-grujicic N, Stevanovic M. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma. Cells 2022;11:2530. [DOI: 10.3390/cells11162530] [Reference Citation Analysis]
11 Prud’homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Front Aging 2022;3. [DOI: 10.3389/fragi.2022.931331] [Reference Citation Analysis]
12 Maria Teresa Palano, Matteo Gallazzi, Martina Cucchiara, Federico Dehò, Paolo Capogrosso, Antonino Bruno, Lorenzo Mortara. The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. Explor Target Antitumor Ther 2022;3. [PMID: 36338516 DOI: 10.37349/etat.2022.00108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]